A report by the FDA staff said they are concerned about Biogen Idec's safety plan for Tysabri if it is allowed back on the market as a treatment for multiple sclerosis, saying the drug could be prescribed to patients with "less severe forms of the disease" that might not justify the risks associated with Tysabri. An advisory panel will meet today to consider the return of the Biogen and Elan Corp. drug.

Related Summaries